Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064051 · ClinicalTrials.gov registry record · Phase 2
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Study locations
NCT00064051 is a Phase 2 study of Pancreatic Cancer that has completed, run by Vion Pharmaceuticals. The trial reports 7 study locations across 6 states.
The verdict
NCT00064051, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving gemcitabine together with 3-AP works in treating patients with unresectable or metastatic pancreatic cancer.
Conditions Studied
Interventions
- DRUG gemcitabine hydrochloride
- DRUG triapine
Study Locations (7)
England
- Christie Hospital N.H.S. Trust - Manchester
- Royal Marsden NHS Foundation Trust - Surrey - Sutton
Illinois
- University of Chicago Cancer Research Center - Chicago
Indiana
- Indiana Oncology Hematology Consultants - Indianapolis
Minnesota
- University of Minnesota Cancer Center - Minneapolis
Tennessee
- Sarah Cannon Cancer Center at Centennial Medical Center - Nashville
Other
- Universitair Ziekenhuis Gent - Ghent
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064051
The ClinicalTrials.gov registry entry for NCT00064051 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Vion Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00064051 reports 7 study locations spanning 6 distinct geographic areas - top geographies include England, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT00064051 about?
NCT00064051 is a clinical study titled "3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them m...
What is the current status of trial NCT00064051?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-01. Estimated completion is 2008-08.
What conditions does trial NCT00064051 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00064051?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), triapine (DRUG).
Who is sponsoring clinical trial NCT00064051?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00064051 being conducted?
This trial has 7 study locations across Illinois, Indiana, Minnesota, Tennessee, England. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.